![](/img/cover-not-exists.png)
Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spondyloarthritis: protocol for a randomised open-label phase III study, AScalate
Poddubnyy, Denis, Hammel, Ludwig, Heyne, Marvin, Veit, Justyna, Jentzsch, Claudia, Baraliakos, XenofonVolume:
10
Journal:
BMJ Open
DOI:
10.1136/bmjopen-2020-039059
Date:
September, 2020
File:
PDF, 336 KB
2020